These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 7519216

  • 1. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA.
    J Immunol; 1994 Aug 15; 153(4):1836-46. PubMed ID: 7519216
    [Abstract] [Full Text] [Related]

  • 2. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
    Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA.
    J Immunol; 1993 Nov 15; 151(10):5726-41. PubMed ID: 8228258
    [Abstract] [Full Text] [Related]

  • 3. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA.
    J Immunol; 1993 Jan 01; 150(1):265-77. PubMed ID: 8417127
    [Abstract] [Full Text] [Related]

  • 4. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 01; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 5. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 6. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Sep 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 7. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM, Waller EK.
    Biol Blood Marrow Transplant; 2004 Aug 01; 10(8):540-51. PubMed ID: 15282532
    [Abstract] [Full Text] [Related]

  • 8. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 9. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
    Imado T, Iwasaki T, Kuroiwa T, Sano H, Hara H.
    Transplantation; 2004 Feb 15; 77(3):391-8. PubMed ID: 14966413
    [Abstract] [Full Text] [Related]

  • 10. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS, Riley R, Hamilton BL, Paupe J, Perez D, Levy RB.
    Bone Marrow Transplant; 1994 Nov 15; 14(5):725-35. PubMed ID: 7889005
    [Abstract] [Full Text] [Related]

  • 11. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

  • 12. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
    Erdmann AA, Jung U, Foley JE, Toda Y, Fowler DH.
    Biol Blood Marrow Transplant; 2004 Sep 01; 10(9):604-13. PubMed ID: 15319772
    [Abstract] [Full Text] [Related]

  • 13. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA.
    J Immunol; 1998 Jun 01; 160(11):5355-65. PubMed ID: 9605135
    [Abstract] [Full Text] [Related]

  • 14. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
    Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA.
    J Immunol; 1991 Sep 01; 147(5):1492-503. PubMed ID: 1831826
    [Abstract] [Full Text] [Related]

  • 15. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Sep 01; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 16. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
    Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, Korngold R, Noelle R, Vallera DA.
    J Immunol; 1997 Jan 01; 158(1):29-39. PubMed ID: 8977172
    [Abstract] [Full Text] [Related]

  • 17. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H.
    J Immunol; 1995 Mar 15; 154(6):2687-96. PubMed ID: 7876541
    [Abstract] [Full Text] [Related]

  • 18. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M, Wettstein PJ, Korngold R.
    Transplantation; 1994 Apr 15; 57(7):1095-102. PubMed ID: 7909395
    [Abstract] [Full Text] [Related]

  • 19. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 Apr 15; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 20. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep 15; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.